EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation

Ana Weidenauer iD, Ulrich Sauerzopf iD, Martin Bauer, Carina Bum, Cornelia Diendorfer, Irena Dajic, Lucie Bartova, Alina Kastner, Karsten Bamminger, Lukas Nics, Cecile Philippe, Marcus Hacker und 4 weitere

Schizophrenia Bulletin · 2024

DOI: 10.1093/schbul/sbae111 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Schizophrenia Bulletin, 2024. Verfasst von Ana Weidenauer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Dextroamphetamine, Dopamine, Psychotic Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anniversary Fund of the Austrian National Bank, Medical Scientific Fund of the Mayor of Vienna, Vienna Science and Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis The dopamine theory of schizophrenia suggests that antipsychotics alleviate symptoms by blocking dopamine D2/3 receptors, yet a significant subset of patients does not respond adequately to treatment. To investigate potential predictors, we evaluated d-amphetamine-induced dopamine release and 1-year clinical outcomes in 21 antipsychotic-naive patients with first-episode schizophrenia. Study Design Twenty-one antipsychotic-naive patients (6 female) underwent dopamine D2/3 receptor radioligand [11C]-(+)-PHNO positron emission tomography. For estimating dopamine release, scans were performed with and without d-amphetamine pretreatment. The Positive and Negative Syndrome Scale was performed at regular intervals over 1 year while receiving treatment in a naturalistic setting (Clinical Trial Registry: EUDRACT 2010-019586-29). Study Results A group analysis revealed no significant differences in d-amphetamine-induced dopamine release between patients with or without clinically significant improvement. However, d-amphetamine-induced dopamine release in ventral striatum was significantly associated with reductions in positive symptoms (r = 0.54, P = .04; uncorrected P-values); release in globus pallidus correlated with a decrease in PANSS negative (r = 0.58, P = .02), general (r = 0.53, P = .04), and total symptom scores (r = 0.063, P = .01). Higher dopamine release in substantia nigra/ventral tegmental area predicted larger reductions in general symptoms (r = 0.51, P = .05). Post-amphetamine binding in putamen correlated positively with negative symptom scores at baseline (r = 0.66, P = .005) and throughout all follow-up visits. Conclusions These exploratory results support a relationship between d-amphetamine-induced dopamine release and the severity and persistence of symptoms during the first year of psychosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DextroamphetamineDopaminePsychotic DisordersAdultFemaleHumansMaleYoung AdultAmphetamineAntipsychotic AgentsGlobus PallidusOutcome Assessment, Health CarePositron-Emission TomographyReceptors, Dopamine D2Receptors, Dopamine D3SchizophreniaVentral StriatumOxazines

Stichwörter der Autor:innen

PETPHNOdopamine releasepatientspsychosisschizophreniasymptoms

Substanzen

AmphetamineAntipsychotic AgentsDextroamphetamineDopamineReceptors, Dopamine D2Receptors, Dopamine D3naxagolideOxazines

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria.
  • Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
  • Douglas Research Centre, Clinical and Translational Sciences Lab, Montreal, Quebec, Canada.
  • Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Department of Clinical Pharmacology, Medical University of Vienna, Austria.
  • Psychosocial Services in Vienna, Vienna, Austria.

ORCID-Profile: Ana Weidenauer, Ulrich Sauerzopf, Matthäus Willeit

Förderung

  • Anniversary Fund of the Austrian National Bank
  • Medical Scientific Fund of the Mayor of Vienna
  • Vienna Science and Technology Fund
  • Austrian Science Fund FWF

Zitieren

APA

Weidenauer, A., Sauerzopf, U., Bauer, M., Bum, C., Diendorfer, C., Dajic, I., Bartova, L., Kastner, A., Bamminger, K., Nics, L., Philippe, C., Hacker, M., Rujescu, D., Wadsak, W., Praschak-Rieder, N., & Willeit, M. (2024). Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae111

Vancouver

Weidenauer A, Sauerzopf U, Bauer M, Bum C, Diendorfer C, Dajic I, et al. Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation. Schizophrenia Bulletin. 2024. doi:10.1093/schbul/sbae111

BibTeX
@article{Weidenauer2024,
  author = {Weidenauer, Ana and Sauerzopf, Ulrich and Bauer, Martin and Bum, Carina and Diendorfer, Cornelia and Dajic, Irena and Bartova, Lucie and Kastner, Alina and Bamminger, Karsten and Nics, Lukas and Philippe, Cecile and Hacker, Marcus and Rujescu, Dan and Wadsak, Wolfgang and Praschak-Rieder, Nicole and Willeit, Matthäus},
  title = {Amphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation},
  journal = {Schizophrenia Bulletin},
  year = {2024},
  doi = {10.1093/schbul/sbae111}
}
Kostenlos starten →